In vivo blockade of tumor necrosis factor-α in patients with rheumatoid arthritis: Longterm effects after repeated infusion of chimeric monoclonal antibody cA2

Journal of Rheumatology

Volumn 27, Issue 2, 2000, Pages 304-310

  Lorenz, Hanns Martin ^a   Grünke, Mathias ^b   Hieronymus, Thomas ^b   Antoni, Christian ^b   Nüsslein, Hubert ^b   Schaible, Thomas F ^b   Manger, Bernhard ^b   Kalden, Joachim R ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

Biologic agents; Rheumatoid arthritis; TNF ; TNF antibody therapy; Treatment

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCLONAL ANTIBODY CA2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOCOMPETENCE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; MIDDLE AGED; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0343384266     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Moreland LW, Bucy RP, Tilden A, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993;36:307-18.
2. Van der Lubbe PA, Reiter C, Breedveld FC, et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993;36:1375-9.
3. Horneff G, Burmester GR, Emmerich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991;34:129-40.
4. Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmüller G, Kruger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Arthritis Rheum 1991;34:525-36.
5. Didry C, Portales P, Andary M, et al. Treatment of rheumatoid arthritis with monoclonal anti-CD4 antibodies. Clinical results [abstract]. Arthritis Rheum 1991;34 Suppl:S92.
6. Strand V, Lipsky PE, Cannon GW, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Arthritis Rheum 1993;36:620-30.
7. Kirkham BW, Thien F, Pelton BK, et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992;19:1348-52.
8. Moreland LW, Sewell KL, Trentham DE, et al. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double blind, placebo controlled trial with open label extension. Arthritis Rheum 1995;38:1177-86.
9. Kremer JM, Petrillo GF, Righy WFC, et al. PhaseI/II open-label trial of DAB389IL-2 administered to patients with active rheumatoid arthritis receiving treatment with methotrexate [abstract]. Arthritis Rheum 1994;37 Suppl:S341.
10. Isaacs JD, Watts RA, Hazleman BL, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
11. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule I. Arthritis Rheum 1994;37:992-9.
12. Wendling D, Radacot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20:259-62.
13. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum 1993;36:1681-90.
14. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
15. Drevlow BE, Lovis R, Haag MA, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996;39:257-65.
16. Beutler B, Cerami A. The common mediator of shock, cachexia and tumor necrosis. Adv Immunol 1988;42:213-20.
17. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 1988;73:449-55.
18. Firestein GS, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990;144:3347-53.
19. Saxne T, Palladino MA, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor α, but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-8.
20. Sung S-SJ, Jung LKL, Walters JA, Chen W, Wang CY, Fu SM. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med 1988;168:1539-44.
21. Sung S-SJ, Bjorndahl JM, Wang CY, Kao HT, Fu SM. Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody. J Exp Med 1988;167:937-44.
22. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;334:244-7.
23. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
24. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
25. Lorenz H-M, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by iv infusion of a chimeric, monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996;156:1646-53.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
27. Knight DM, Trinh H, Le J. Construction and initial characterisation of a mouse-human chimaeric anti-TNF antibody. Molec Immunol 1993;30:1443-53.
28. Tessier P, Audette M, Cattaruzzi P, McColl SR. Upregulation by tumor necrosis factor alpha of intercellular adhesion molecule-1 expression and function in synovial fibroblasts and its inhibition by glucocorticoids. Arthritis Rheum 1993;36:1528-39.
29. Gerritsen MF, Kelley KA, Ligon G, et al. Regulation of the expression of intercellular adhesion molecule I in cultured human endothelial cells derived from rheumatoid synovium. Arthritis Rheum 1993;36:593-602.
30. Maini RV, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
31. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
32. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
33. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
34. Kalden-Nemeth D, Grebmeier J, Antoni C, Manger B, Wolf F, Kalden JR. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol Int 1997;16:249-55.
35. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. The pivotal role of tumor necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 1992;107:660-4.